Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors

Ann Oncol. 2017 Nov 1;28(11):2882-2887. doi: 10.1093/annonc/mdx480.

Authors

D Sellami¹, B Dharan², C Wilke³, S J Scherer⁴, S Hirawat²

Affiliations

¹ Department of Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, USA. Electronic address: dalila.sellami@novartis.com.
² Department of Oncology Global Development, Novartis Pharmaceuticals Corporation, East Hanover, USA.
³ Department of Oncology Global Development, Novartis Pharma AG, Basel, Switzerland.
⁴ Department of Academic Medical Innovation, Novartis Pharmaceuticals Corporation, East Hanover, USA.

PMID: 28950291
DOI: 10.1093/annonc/mdx480

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Breast Neoplasms / blood
Breast Neoplasms / drug therapy*
Breast Neoplasms / enzymology
Breast Neoplasms / genetics*
Circulating Tumor DNA / blood*
Circulating Tumor DNA / genetics
Female
Humans
Phosphoinositide-3 Kinase Inhibitors*
Protein Kinase Inhibitors / therapeutic use*
Randomized Controlled Trials as Topic

Substances

Circulating Tumor DNA
Phosphoinositide-3 Kinase Inhibitors
Protein Kinase Inhibitors